Every dollar spent on COVID-19 vaccine development and distribution generated up to $809 in economic value during the first year of the rollout, according to a global analysis published in PLOS Medicine.
Vaccine Development and Delivery Costs Totaled $79.4 Billion
The research evaluated vaccine-related costs and benefits across 173 countries from December 8, 2020, to December 8, 2021, capturing the period when vaccination had its greatest impact due to limited population immunity against SARS-CoV-2. Worldwide development and delivery totaled $79.4 billion. This included $13.2 billion in public and nonprofit investments and $14.1 billion in private-sector funding.
Delivery expenses reached $8.94 billion. Governments including those of the United States, China, and European Union countries provided funding to reduce financial risks for manufacturers, according to Telegraph India.
The campaign prevented 1.5 billion infections. It also prevented 51.5 million hospitalizations, generating $564 billion in productivity savings and $222 billion in averted healthcare costs.
Total benefits reached between $6.43 trillion and $64.3 trillion. This translated to a return on investment ranging from $59.70 to $809 per dollar spent.
“While developing and rolling out these vaccines at unprecedented speed required substantial upfront investment, the health and economic benefits far outweighed the costs within just one year,” said Hallie Benjamin, lead author of the paper who worked on the research as a MSc Public Health student at the London School of Hygiene & Tropical Medicine (LSHTM).
“Our study provides evidence that the unprecedented, rapid investments made into COVID-19 vaccines early in the pandemic paid off massively both in health and economic benefits,” said Mark Jit, professor of global health at New York University School of Global Public Health.
Epidemiological modeling indicates that vaccination averted 19.8 million deaths worldwide during its initial year, representing a 63% reduction in overall mortality.
Gregory Barnsley of LSHTM and Oliver Watson of Imperial College London are additional study authors. The study was funded by the UK’s National Institute for Health and Care Research Health Protection Research Unit in Modelling and Health Economics, which is a partnership between the UK Health Security Agency, Imperial College London, and the London School of Hygiene & Tropical Medicine under grant code NIHR200908.
Richard Carpiano at the University of California, Riverside, said that while the life-saving success of the vaccines was already known, this research reinforces the principle that protecting public health serves to protect the economy.
Income Disparities in Global Access
high-income countries gained greater economic benefits due to early access, higher uptake, faster rollouts, and older populations facing higher risks of severe outcomes. Many low- and middle-income nations lacked widespread access until late 2021.
Many residents in those regions had already contracted the virus by then. Despite those distribution delays, low-income countries still recorded the highest savings in healthcare and productivity costs relative to their own economies.
“The lesson is there should be a way to get this vaccine to countries that need it faster,” Jit said, noting that delays limited usefulness in those regions.
Earlier coverage: Florida Study Compares Pfizer and Moderna Vaccine Outcomes
